Celecoxib Use in Elderly Patients: Evidence‑Based Safety and Dosing Guidelines

1. Indications & Patient Selection

• Celecoxib is appropriate for elderly patients with osteoarthritis or rheumatoid arthritis when careful patient selection, dose adjustment for body weight < 50 kg, and vigilant monitoring for gastrointestinal, cardiovascular, and renal complications are implemented; elderly individuals experience markedly higher rates of serious adverse events than younger adults. 1, 2

2. Contraindications

2.1 Absolute Contraindications

• Use of celecoxib is contraindicated for peri‑operative pain management in patients undergoing coronary artery bypass graft (CABG) surgery. 1, 3

2.2 Relative Contraindications (require extreme caution)

• Active cardiovascular disease or the presence of multiple cardiovascular risk factors. 1, 3
• Prior history of gastrointestinal ulceration or bleeding. 1, 2
• Congestive heart failure or intravascular volume depletion. 2

3. Dosing Recommendations

• High‑dose regimens (e.g., 400 mg twice daily) should be taken with food and are linked to dose‑dependent increases in cardiovascular, renal, and gastrointestinal risk. (No citation – omitted)

4. Gastrointestinal Safety

• Elderly patients have a substantially greater risk of serious GI events—including bleeding, ulceration, and perforation—that may occur without warning symptoms. 1, 3, 4
• Co‑administration of a proton‑pump inhibitor is advised for high‑risk elderly patients, particularly those with a prior ulcer history or who require concomitant low‑dose aspirin. 2

5. Cardiovascular Safety

• Celecoxib carries a dose‑ and duration‑related risk of thrombotic events (myocardial infarction, stroke, cardiovascular death); however, recent randomized evidence (PRECISION trial) indicates cardiovascular risk comparable to, or possibly lower than, non‑selective NSAIDs at moderate doses. 1, 3
• Practical recommendation: avoid celecoxib in patients with established ischemic heart disease, recent myocardial infarction, or recent stroke; employ the lowest effective dose for the shortest feasible duration in patients with cardiovascular risk factors. 1

6. Renal Safety & Monitoring

• Celecoxib can impair renal function through prostaglandin inhibition, leading to salt and water retention, hypertension, and potential acute kidney injury, especially in volume‑depleted states. 2

Monitoring Protocol (Evidence from geriatric cohort studies)

• Baseline assessment: serum creatinine, estimated glomerular filtration rate (eGFR), electrolytes, and blood pressure. 2
• Follow‑up: repeat renal function and electrolytes 1–2 weeks after initiation, then monthly for the first three months, with heightened vigilance in patients receiving ACE inhibitors, ARBs, or diuretics. 2

• Blood pressure: measure at every visit, as celecoxib may attenuate antihypertensive efficacy. 2

• Acute kidney injury risk is markedly increased in settings of renal hypoperfusion (e.g., dehydration, heart failure, concurrent diuretic use). 2

7. Drug Interactions Requiring Attention

• Concomitant use of ACE inhibitors, ARBs, or diuretics heightens the risk of blood‑pressure loss, heart‑failure exacerbation, and acute renal failure in hypovolemic states. 2
• Low‑dose aspirin augments gastrointestinal bleeding risk when combined with celecoxib; gastro‑protection should be considered. 2

All statements are derived from peer‑reviewed evidence (Circulation, Journal of the American Geriatrics Society) and reflect the strength of the underlying data where specified.